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TSC2/mTORC1 signaling controls Paneth and goblet
cell differentiation in the intestinal epithelium
Y Zhou1,3, P Rychahou1,2,3, Q Wang1,2, HL Weiss1 and BM Evers*,1,2
The intestinal mucosa undergoes a continual process of proliferation, differentiation and apoptosis, which is regulated by multiple
signaling pathways. Notch signaling is critical for the control of intestinal stem cell maintenance and differentiation. However, the
precise mechanisms involved in the regulation of differentiation are not fully understood. Previously, we have shown that tuberous
sclerosis 2 (TSC2) positively regulates the expression of the goblet cell differentiation marker, MUC2, in intestinal cells. Using
transgenic mice constitutively expressing a dominant negative TSC2 allele, we observed that TSC2 inactivation increased mTORC1
and Notch activities, and altered differentiation throughout the intestinal epithelium, with a marked decrease in the goblet and
Paneth cell lineages. Conversely, treatment of mice with either Notch inhibitor dibenzazepine (DBZ) or mTORC1 inhibitor rapamycin
significantly attenuated the reduction of goblet and Paneth cells. Accordingly, knockdown of TSC2 activated, whereas knockdown
of mTOR or treatment with rapamycin decreased, the activity of Notch signaling in the intestinal cell line LS174T. Importantly,
our findings demonstrate that TSC2/mTORC1 signaling contributes to the maintenance of intestinal epithelium homeostasis by
regulating Notch activity.
Cell Death and Disease (2015) 6, e1631; doi:10.1038/cddis.2014.588; published online 5 February 2015
The intestinal epithelium undergoes a process of constant and
rapid renewal. The intestinal crypts of Lieberkühn, a highly
dynamic niche with multipotent stem cells residing in its lower
third, generate new cells that eventually differentiate into the
four specialized cell types of the small intestine, namely
absorptive enterocytes and secretory lineages known as
enteroendocrine, goblet and Paneth cells.1,2 Differentiated
enterocytes, which make up the majority of the cells of the gut
mucosa, then undergo a process of apoptosis and are
extruded into the lumen.1,3 The mechanisms that regulate
stem cell maintenance, proliferation, differentiation and
apoptosis must be precisely orchestrated to ensure proper
organ maintenance.3 An imbalance in this highly-regimented
and orderly process within the intestinal crypts is associated
with a number of intestinal pathologies, including colorectal
cancer, inflammatory bowel disease (IBD) and necrotizing
enterocolitis.4–6 To date, the cellular mechanisms regulating
intestinal cell differentiation are not entirely known.
Tuberous sclerosis is an autosomal dominant disorder
caused by the mutations in the tuberous sclerosis 2 (TSC2)
gene.7 TSC1 and TSC2 function as a complex and exert their
tumor suppressor function by negatively regulating the mTOR
pathway.8 mTOR is a member of the phosphatidylinositol
3-kinase-related kinase family and regulates protein transla-
tion, cell cycle progression and cell proliferation.9 The TOR
signaling events are essential for epithelial growth, morpho-
genesis and differentiation in the vertebrate intestine.10 mTOR
exists in two complexes: mTORC1 (containing mTOR, Raptor
etc.) and mTORC2 (containing mTOR, Rictor etc.). REDD1 is
proposed to inhibit mTORC1 by displacing TSC2 from the
14-3-3-binding protein, thus allowing TSC2 to inhibit
mTORC1.11 The bacterially derived drug rapamycin allosteri-
cally inhibits mTORC1 activity.12
Notch signaling is involved in the control of proliferation,
differentiation and development.13 Binding of cell surface-
tethered ligands (Delta and Jagged) to Notch receptors on
neighboring cells initiates a series of cleavages in the Notch
receptor. The final cleavage releases the Notch intracellular
domain (NICD), which translocates into the nucleus and acts
as a transcriptional coactivator that promotes gene expres-
sion. Hairy/enhancer of split 1 (Hes1) is one of the best-
characterized target genes of the Notch signaling pathway.
The Notch-Hes1 pathway promotes the proliferation of
intestinal stem/progenitor cells and inhibits secretory cell
development.14–16 Hes1 functions as a downstream target of
both the Notch and Wnt signaling pathway in LS174T colon
cancer cells,17 suggesting that crosstalk between Notch and
Wnt signaling may take place via Hes1.
Previously, we reported that REDD1/TSC2/mTOR signaling
pathway regulates Notch signaling and the expression
of mucin2 (MUC2), a goblet cell differentiation marker, in
intestinal cell lines.18,19 In our current study, we used
transgenic (TG) mice constitutively expressing a dominant
negative TSC2 allele, to further elucidate the role of mTOR
signaling pathway during the turnover of the intestinal
epithelium, including its crosstalk to Notch signaling. We
found that TSC2 inactivation increased mTORC1 and Notch
activities and disrupted goblet and Paneth cell differentiation.
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Conversely, treatment of mice with dibenzazepine (DBZ) or
rapamycin attenuated the decrease of goblet and Paneth cell
generation induced by TSC2 inactivation. Our study demon-
strates that TSC2/mTORC1 signaling has an important role
in the maintenance of intestinal epithelium homeostasis.
Thus, aberrant mTOR signaling may result in an imbalance
in the proliferation, differentiation and apoptosis patterns
within the intestinal crypts, which is associated with a number
of intestinal pathologies.
Results
TSC2 is essential for intestinal cell differentiation. Pre-
viously, using in vitro cell lines, we showed that TSC2
contributes to intestinal goblet cell differentiation.19 To further
delineate the role of TSC2 in intestinal differentiation, we
used TG mice with mutated TSC2. Because TSC2-null mice
die in utero,20 we obtained mice TG for a TSC2 allele lacking
Rheb-GTPase-activating protein function (TSC2-RGΔ). This
mouse model has been used to study the role of TSC2/
mTOR in various types of tissues.21–23
First, we confirmed the presence of the ΔRG transgene by
standard PCR using DNA from wild type (WT) and TG mice
and primers, as previously described21–23 (Supplementary
Figure 1). In TG mice, the intestine appeared normal by
histology (Supplementary Figure 2), with no change in
apoptotic cell numbers (Supplementary Figure 3). We next
determined whether the loss of TSC2 function in TSC2-ΔRG
mice resulted in the activation of mTOR signaling in the
intestine. Increased phosphorylation of S6, a marker of
mTORC1 activity, is noted in TG mice compared with their
WT controls as determined by immunohistochemistry (IHC)
(Figure 1a). Similarly, in immunoblots from isolated intestinal
mucosa, phosphorylation of S6 was increased in TG mice
(Figure 1b). In agreement with the increased phosphorylation
of S6, increased phosphorylation of 4E-BP, another marker of
mTOR activity, was also detected in TG mice compared with
WT control (Supplementary Figure 4). These results confirm
that TSC2 inactivation results in the activation of mTORC1
signaling in intestinal epithelium. mTORC1 activation con-
tributes to intestinal cell proliferation.24,25 Consistently,
increased cell proliferation was noted in TG mice as analyzed
by Ki67 IHC staining (Supplementary Figure 5).
We showed that mTORC1 positively regulates Notch
signaling in intestinal cell lines.18 Because Notch signaling
has a critical role in the regulation of secretory cell differentia-
tion, the effect of TSC2 inactivation on intestinal cell
differentiation was next determined. MUC2 expression, a
goblet cell marker, was markedly decreased in both the colon
and small bowel of TSC2-mutant TG mice as noted by Alcian
blue, IHC and western blotting (Figures 1c and g). Consistent
with our in vivo findings, we previously showed that
the knockdown of TSC2 decreased MUC2 expression in the
intestinal cell line HT29.19 Together, our findings using both
in vitro and in vivo models demonstrate that TSC2 is required
for intestinal goblet cell differentiation.
Remarkably, staining of intestinal sections from TSC2-
mutant TG mice for lysozyme, an early marker of Paneth cell
differentiation, revealed that almost all the crypts were
completely devoid of Paneth cells (Figures 2a and b). The
effects of TSC2 inactivation on Paneth cells have also been
determined by IHC staining for MMP7, another Paneth cell
marker.26
Consistent with the decreased lysozyme staining,
decreased staining of MMP7 was also found in TSC2-
mutant mice (Supplementary Figure 6). In addition, decreased
enteroendocrine cell numbers were found in TSC2-mutant TG
mice as assessed by chromogranin A staining (Supple-
mentary Figure 7). Therefore, these results demonstrate that
TSC2 is required for differentiation of intestinal secretory cell
lineage.
TSC2 controls intestinal cell differentiation through
regulation of Notch/Hes1 signaling. Inhibition of the Notch
pathway leads to an increase in intestinal secretory cell
differentiation.1,27,28 Loss of TSC promotes Notch activation
in Drosophila, rodents and humans,29 although proof is
lacking that inactivation of TSC2 mediates Notch1 activation
in intestinal cells. To determine whether TSC2 inactivation
promotes Notch signaling in intestinal epithelium, we
compared the expression of NICD and Hes1 in TSC2-
mutant TG versus WT mice. The expression of NICD and
Hes1 was markedly increased in the TSC2-mutant mice as
shown by IHC (Figure 3a) and western blot (Figure 3b).
These results demonstrate the negative regulation of Notch
signaling by TSC2 in intestinal epithelium, reinforcing the
notion that TSC2 controls intestinal cell differentiation through
the regulation of Notch signaling.
To further demonstrate that TSC2 regulates intestinal cell
differentiation through Notch signaling, we next determined
whether inhibition of Notch with DBZ attenuates the repression
of intestinal cell differentiation induced by TSC2 inactivation in
the intestine. Administration of DBZ for 5 days effectively
rescued the effect of TSC2 inactivation as shown by the
increased number of goblet and Paneth cells (Figure 3c). The
inhibition of Notch signaling was confirmed by the decreased
NICD expression. These data demonstrate that TSC2
regulates goblet and Paneth cell differentiation through Notch
signaling.
TSC2 regulates intestinal cell differentiation via inhibition
of mTOR signaling. Because we previously showed
that REDD1/TSC2/mTOR signaling pathway regulates the
expression of MUC2 in intestinal cell lines,18,9 we next
determined whether the inhibition of mTOR with rapamycin
attenuates the repression of goblet and Paneth cell differ-
entiation induced by TSC2 inactivation in the intestine.
Administration of rapamycin for 6 days decreased phos-
phorylated S6 expression and, importantly, increased goblet
cells in the intestine, thus effectively rescuing the effect of
TSC2 inactivation (Figures 4a and c). Similarly, Paneth cells
were also increased by administration of rapamycin (Figures
4d and e). These data indicate that TSC2 regulates goblet
and Paneth cell differentiation through mTOR signaling.
TSC2/mTOR signaling regulates intestinal cell differen-
tiation by interfering with Notch signaling in intestinal
epithelium. TSC2 negatively regulates Notch1 signaling
in an mTOR-dependent and -independent fashion.30,31
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Figure 1 TSC2 inactivation results in altered goblet cell differentiation. (a) Immunohistochemical (IHC) staining demonstrated increased expression of phospho-S6 (some are
indicated by arrows) in intestinal epithelium of TG mice compared with WT mice. (b) Mucosal protein lysates extracted fromWTand TG mice were used for western blot detection
of phospho-S6 and total S6 protein expression. The levels of p-S6 were quantitated densitometrically and expressed as fold change with respect to total S6. (c and d) Alcian blue
(AB) staining of the intestine revealed a reduction in mucinous goblet cells in TSC2-mutant TG mice compared with WT mice (c, some are indicated by arrows). (d) Quantification
of AB-positive cells in WT- and TSC2-mutant TG mice. (Data represent mean±S.D.; *Po0.05 versusWT). (e and f) (IHC) staining for MUC2 further confirmed the decrease in
goblet cells in TSC2-mutant TG mice compared with WT mice (e, some are indicated by arrows). (f) Quantification of MUC2-positive cells in WT- and TSC2-mutant TG mice.
(Data represent mean± S.D.; *Po0.05 versus WT). (g) Mucosal protein lysates extracted from WT and TG mice were used for western blot detection of MUC2 protein
expression. Scale bars, 50 μm
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To address whether TSC2 inactivation leads to the increase
of Notch signaling through mTOR activation, we first
transfected the human colon cancer cell line LS174 with
siRNA-targeting TSC2 or non-targeting control (NTC)
siRNA (Figure 5a). Knockdown of TSC2 increased the
Notch transactivator NICD domain and Hes1 expression,
suggesting TSC2-negative regulation of Notch signaling in
LS174T cells. We next treated HT29 cells with rapamycin
and, as shown in Figure 5b, treatment with rapamycin
decreased the Notch transactivator NCID domain and Hes1
expression, suggesting the regulation of Notch signaling by
mTOR. To further confirm the regulation of Notch by mTOR,
LS174T cells were transfected with siRNA-targeting mTOR
and the expression of NICD and Hes1 was determined.
Knockdown of mTOR decreased the protein expression of
NICD and Hes1, demonstrating mTOR-positive regulation of
Notch signaling (Figure 5c). To determine whether mTOR
regulates the expression of MUC2, RNA from LS174T cells
transfected with either NTC siRNA or mTOR siRNA was
used for analysis of MUC2 mRNA expression by real-time
RT-PCR. Knockdown of mTOR significantly increased MUC2
mRNA expression in LS174T cells (Figure 5d). These results
demonstrate the regulation of MUC2 expression by the
TSC2/mTOR/Notch signaling pathway in LS174T cells.
Finally, we determined whether inhibition of mTOR with
rapamycin attenuated the increased NICD and Hes1 expres-
sion mediated by TSC2 inactivation in mouse intestinal
epithelium. As shown in Figure 6, TSC2 inactivation leads to
increased NICD and Hes1 expression as expected; this
increase was significantly attenuated by administration of
rapamycin as shown by IHC (Figure 6a) and western blot
(Figure 6b). Taken together, our results demonstrate the
regulation of intestinal goblet and Paneth cell differentiation by
the TSC2/mTOR/Notch signaling pathway.
Discussion
The upstream mechanisms that initiate and control intestinal
differentiation remain largely undefined. We showed that
activation of mTORC1 decreased, whereas inhibition of
mTORC1 increased, goblet cell differentiation in human
intestinal cell lines.18,19 We now provide evidence and
demonstrate the role of TSC2/mTOR in the differentiation of
intestinal cells in vivo. Mutant TSC2 mice demonstrate an
activation of mTORC1 and Notch signaling along with an
obvious decrease in goblet and Paneth cells in the intestine;
this reduction was markedly attenuated by DBZ or rapamycin
treatment. Consistently, knockdown of TSC2 activates,
whereas knockdown of mTOR inhibits, Notch signaling in the
human colon cancer cell line LS174T. Taken together,
our results demonstrate that intestinal cell differentiation is
regulated by TSC2/mTOR/Notch signaling (Figure 7).
mTOR has been implicated in the signaling pathways
regulating cell growth, apoptosis and differentiation of various
cell types.32–34 Recently, we showed that inhibition of
mTORC1 contributes to goblet cell differentiation in human
intestinal cell lines.18,19 In our present study, we show that the
TSC2/mTORC1 signaling pathway has a critical role in the
regulation of intestinal goblet and Paneth cell differentiation in
mice. Consistent with our findings, Yilmaz et al.,35 showed that
administration of rapamycin for 4 weeks increased the
frequency of Paneth cells in the mouse intestine. Moreover,
loss of Adenomatous polyposis coli (APC) in mice results in an
absence of goblet cells; conversely, treatment with rapamycin
restored goblet cell numbers.25 HDAC1- and HDAC2-deficient
mice demonstrated increased mTORC1 activity correlating
with reduction of goblet and Paneth cells in the intestine.36
Furthermore, dysregulated differentiation within the intestinal
crypts is associated with the progression of colorectal cancer.5
We previously demonstrated elevated mTOR activity and
overexpression of mTOR complex components in CRC.37,38
Treatment with rapamycin has been shown to inhibit the
polyposis and progression to dysplasia induced by
APC mutation.25 Taken together, our studies and those of
others25,35,36 demonstrate the regulation of intestinal differ-
entiation by mTORC1 signaling.
The interaction between TSC2/mTOR and Notch signaling
has been noted in various cell types. On the one hand, TSC2/
mTOR acts as an upstream regulator of Notch signaling.
Our results show that TSC2 inhibits mTORC1, leading to the
inhibition of Notch signaling in intestinal cells. Similarly, TSC2
has been shown to inhibit Notch through the inhibition of
mTORC1 signaling in MEF cells and in some cancer cell
lines.30 In addition, TSC2 has been shown to inhibit Notch in
anmTOR-independent fashion.31 Conversely, Notch signaling
increases mTOR signaling in certain cell types. For example,
Notch signaling promotes hepatic lipogenesis through activa-
tion of mTORC1.39 In addition, Notch promotes mTORC1
signaling by increasing the levels of Raptor, a core component
of mTORC1, as well as mTORC1 assembly. Notch also
suppresses TSC2 expression and regulates cell differentiation
in theDrosophila intestinal stem cell lineage.40 Together, these
Figure 2 TSC2 inactivation results in altered Paneth cell differentiation in
intestine. (a) Immunohistochemical (IHC) staining of the small intestine for lysozyme
showed the decrease in Paneth cells (arrow) in TSC2-mutant TG mice compared with
WT mice. (b) Quantification of lysozyme-positive cells in WT and TSC2-mutant TG
mice. (Data represent mean±S.D.; *Po0.05 versus WT). Scale bars, 50 μm
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studies suggest that two major biochemical pathways,
the TSC2/mTOR pathway and the Notch/Hes1 pathway,
cooperate to control cellular differentiation in vivo. It remains
to be seen whether Notch signaling also regulates TSC2/
mTOR signaling in intestinal cells.
We showed that inactivation of TSC2 leads to a profound
decrease of goblet and Paneth cell lineages in the intestine
and that this reduction was significantly attenuated
by inhibition of mTORC1 using rapamycin. However, these
decreased goblet and Paneth cells were not completely
Figure 3 TSC2 inactivation leads to the increased Notch signaling in intestine. (a) Immunohistochemical (IHC) staining (arrow) for NICD and Hes1 demonstrated increased
expression in the intestinal epithelium of TG mice compared with WT mice. (b) Mucosal protein lysates extracted from WTand TG mice were used for western blot detection of
NICD and Hes1 protein expression. (c) TSC2-mutant TG mice were treated with or without DBZ for 5 day. The inhibition of Notch signaling by DBZ was demonstrated by staining
with NICD (arrow). The goblet cell population, revealed by Alcian blue staining (arrow) and Paneth cells, assessed by IHC staining of lysozyme (arrow), are reduced in the small
intestinal epithelium of TSC2-mutant TG mice. Treatment with DBZ restored the goblet and Paneth cell numbers. (Data represent mean± S.D.; *Po0.05 versus WT alone;
#Po0.05 versus TG alone). Scale bars, 50 μm
TSC2/mTORC1 regulates intestinal differentiation
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restored by mTOR inhibition. As TSC2 has been shown to
inhibit Notch in an mTOR-independent fashion,31 inactivation
of TSC2 may also activate Notch signaling independent of
mTOR regulation in intestinal cells. Indeed, deletion of LKB1
results in the activation of Notch-Hes5 signaling and thus
alteration of intestinal goblet and Paneth cell differentiation
through an mTOR-independent fashion.41 The LKB1/AMPK
signaling cascade negatively regulates mTOR by phosphor-
ylating and activating TSC2.42 Therefore, TSC2 likely inhibits
Notch and regulates intestinal goblet and Paneth cell
differentiation through mechanisms that are both dependent
and independent of mTOR.
IBD, most notably Crohn’s disease (CD) and ulcerative
colitis (UC), is associated with defects in stem cell differentia-
tion, resulting in a decrease of Paneth cells in CD or goblet
cells in UC.4,43 Paneth cells utilize the secretion of defensins
and other microbicidal peptides to kill invasive pathogens,
shape the intestinal microbiota and protect intestinal stem
cells from harm.44 Mucins, secreted by goblet cells, protect the
epithelial surface of the GI tract by forming a semi-permeable
mucous layer between the lumen and the intestinal
epithelium.45,46 Diminished Paneth cell differentiation results
in a defective antimicrobial barrier in CD, whereas in UC,
an insufficient induction of goblet cell mucins can lead to a
disturbed mucosal barrier. Elevated mTOR activity has been
identified in the colonic epithelial cells of human IBD patients
with active disease.47 Inhibitors of TORC1 have proven to be
effective in IBD.48,49 In addition, there are two case reports,
indicating that the mTOR inhibitors, sirolimus and everolimus,
induce remission in refractory CD patients.50,51 These findings
Figure 4 TSC2/mTOR signaling pathway controls differentiation of the goblet and Paneth cell lineages. WT- and TSC2-mutant TG mice were treated with or without
rapamycin for 6 days. The inhibition of mTORC1 signaling by rapamycin was demonstrated by staining with phospho-S6 (a, arrow). The goblet cell population, revealed by Alcian
blue staining and MUC2 immunostaining (b, arrow; c), and Paneth cells, assessed by immunohistochemical staining of lysozyme (d, arrow; e), are reduced in the small intestinal
epithelium of TSC2-mutant TG mice. (Data represent mean±S.D.; *Po0.05 versus WTalone; #Po0.05 versus TG alone). Treatment with rapamycin restored the goblet and
Paneth cell numbers. Scale bars, 50 μm
TSC2/mTORC1 regulates intestinal differentiation
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suggest that targeting mTOR may offer a promising therapeu-
tic strategy for the treatment of IBD.
In conclusion, we report that TSC2/mTOR signaling
regulates intestinal cell differentiation in a Notch-dependent
manner, thus providing a better mechanistic understanding of
mTOR inhibition and its potential beneficial effects in certain
intestinal diseases. Our current in vivo findings further expand
our earlier in vitro reports in which knockdown of TSC2
inhibited, whereas inhibition of mTOR increased, goblet
cell differentiation in colon cancer cells. Taken together, our
data support a novel role of TSC2/mTOR in the regulation of
Notch signaling and the maintenance of intestinal epithelial
homeostasis.
Materials and Methods
Mice. C57BL/6 and TSC2- ΔRG TG mice (strain name C57BL/6-Tg (CMV-Tsc2*)
1 Arbi/KlanJ, stock number 014564) were purchased from the Jackson Laboratory
(Sacramento, CA, USA), maintained on a 12-h light/dark schedule in filter top
isolators with autoclaved water under specific pathogen-free conditions, and fed
autoclaved standard laboratory chow ad libitum. Genotypes of mice were
determined from DNA isolated by ear punch with the use of DNeasy Blood &
Tissue Kit (Qiagen, Valencia, CA, USA). DBZ (Selleckchem, Radnor, PA, USA), was
injected intraperitoneally (i.p.) daily for 5 days at 30 μmol/kg. DBZ was finely
suspended in 0.5% (w/v) hydroxypropylmethylcellulose (Methocel E4M) and 0.1%
(w/v) Tween 80 in water as described.28 Rapamycin (LC Laboratories, Woburn, MA,
USA), administered by i.p. injection daily for 6 days at 4 mg/kg, was reconstituted in
absolute ethanol at 10 mg/ml and diluted in 5% Tween 80 (Sigma) and 5% PEG-400
(Hampton Research, Aliso Viejo, CA, USA) before injection as described
previously.35 The final volume of all injections was 200 μl. The ileum and cecum
from TSC2-mutant and WT mice were harvested, opened and washed with ice-cold
PBS. Half of the sample was used for IHC; the mucosa from the other portion was
scraped with glass slides, placed into cell lysis buffer and immediately snap frozen
in liquid N2. Samples were homogenized in cell lysis buffer by stainless steel blend
bead beating (0.9–2.0 mm; 5 m, 4 °C) using a Bullet Blender (Next Advance Inc,
Averill Park, NY, USA). Cell lysis buffer (Cell Signaling, Beverly, MA, USA) was
supplemented with 1 mM PMSF and protease inhibitor cocktails (complete mini and
Figure 5 TSC2/mTOR is an upstream regulator of Notch-Hes1 signaling in the human colon cancer cell line LS174T. (a) LS174T cells were transfected with non-targeting
control (NTC) siRNA or siRNA-targeting TSC2. (b) LS174T cells were treated with 100 nM rapamycin for 24 h. (c) LS174T cells were transfected with NTC siRNA or siRNA-
targeting mTOR. Total protein was extracted and western blotting performed using anti-NICD, anti-Hes1, anti-TSC2, anti-mTOR, anti-p-S6, anti-S6 and anti-β-actin antibodies.
(d) LS174T cells were transfected with NTC siRNA or siRNA-targeting mTOR; total RNA was extracted and MUC2 mRNA levels were determined by real-time RT-PCR.
(Data represent mean± S.D.; *Po0.05 versus NTC siRNA)
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complete ultra, EDTA-free; one tablet per 10 ml lysis buffer; Roche, Indianapolis, IN,
USA). All animal procedures were conducted with approval and in compliance with
University of Kentucky Institutional Animal Care and Use Committee.
Cell culture, transfection and treatment. The human colon cancer cell
line, LS174T, was maintained in RPMI supplemented with 5% FCS. Cells were
transfected with the siRNA duplexes by electroporation (Gene Pulser, Bio-Rad,
Hercules, CA, USA) as we have described previously.52,53 Human TSC2, mTOR
and NTC siRNA SMARTpool were purchased from Dharmacon, Inc. (Lafayette, CO,
USA). siRNA SMARTpool, consisting of four siRNA duplexes, was designed using
an algorithm comprised of 33 criteria and parameters that effectively eliminate non-
functional siRNA.54
Figure 6 TSC2/mTOR signaling pathway regulates intestinal cell differentiation through Notch1. (a) WTand TG mice were treated with or without rapamycin for 6 days. The
decreased immunohistochemical staining for NICD and Hes1 (arrow) demonstrated the inhibition of Notch signaling by rapamycin in the intestinal epithelium. (b) Mucosal protein
lysates extracted fromWTand TGmice treated with or without rapamycin for 6 days were used for western blot detection of NICD and Hes1 protein expression. Scale bars, 50 μm
TSC2/mTORC1 regulates intestinal differentiation
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Western blot analysis. Total protein was resolved on a 10% polyacrylamide
gel and transferred to polyvinylidene fluoride membranes. Membranes were
incubated for 1 h at room temperature in blotting solution. Antibodies to TSC2
(Santa Cruz, CA, USA), mTOR, phospho-S6 (pS235/236), S6 and phospho-4E-BP1
(Thr37/46) (all from Cell Signaling), MUC2 and Notch1 (NICD) (both from Epitomics
Inc., Burlingame, CA, USA), Hes1 (Millipore, Billerica, MA, USA) and β-actin
(Sigma, St. Louis, MO, USA) were added, and following blotting with a horseradish
peroxidase-conjugated secondary antibody, protein expression was visualized using
an enhanced chemiluminescence detection system.
Quantitative real-time RT-PCR analysis. Total RNA was extracted and
treated with DNase (RQ1, Promega, Madison, WI, USA). Synthesis of cDNA was
performed with 1 μg of total RNA using reagents in the TaqMan Reverse
Transcription Reagents Kit (ABI #N8080234). TaqMan probe and primers for human
MUC2 and GAPDH were purchased from Applied Biosystems (Foster City, CA,
USA). Quantitative real-time RT-PCR analysis was performed with an Applied
Biosystems Prism 7000HT Sequence Detection System using TaqMan universal
PCR master mix as we have described previously.55
IHC and Alcian Blue (AB) staining and TUNEL assay. Tissue was
processed for routine IHC staining using the following antibodies: rabbit anti-
Lysozyme (Diagnostic BioSystems, Pleasanton, CA, USA; RP 028-05), rabbit
monoclonal anti-Notch1 (NICD) antibody (Epitomics Inc. 1935-1), anti-Hes1
(Millipore, 5702), anti-MUC2 (Santa Cruz, SC15334), anti-phospho-S6 (pS235/236)
(Cell Signaling, #4858), rabbit chromogranin A (Abcam, Cambridge, MA, USA;
15160), mouse MMP7 (R&D Systems, Minneapolis, MN, USA; AF2967) and rabbit
Ki67 (Novus, Littleton, CO, USA; NB110-89717). Negative controls (including no
primary antibody or isotype-matched mouse immunoglobulin G) were used in each
assessment. AB staining was performed according to standard protocol using AB
pH 2.5 Stain Kit (Dako, Carpinteria, CA, USA; AR160). Apoptotic cells were
detected by TUNEL assay using an ApopTag Peroxidase In Situ Apoptosis
Detection Kit (Millipore, S7100).
Statistical analysis. Comparisons of the number of AB+, MUC2+, lysozyme+
in the intestine were performed between WT- and TSC2-mutant mice using the
linear mixed model to account for multiple observations from multiple crypts per
mouse. Pairwise comparisons, specified a priori, were performed using contrast
statements from the model. Two-sample t-test was used for comparison of qRT-PCR
between control siRNA versus mTOR siRNA. Bar graphs represent mean±S.D.
levels in each group. P-values o0.05 were considered statistically significant.
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